Financials in USD. Standardized financial statements.
A compact view of how Clinuvel Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $95.02M | $88.18M | $78.32M | $65.72M | $47.98M | $32.57M | $31.05M | $25.49M | $16.77M | $6.82M |
| Revenue Growth? | +7.8% | +12.6% | +19.2% | +37.0% | +47.3% | +4.9% | +21.8% | +52.0% | +145.8% | 0.0% |
| Cost of Revenue? | $15.88M | $7.73M | $27.73M | $19.10M | $12.77M | $14.13M | $445,355 | $949,770 | $615,078 | $1.94M |
| Gross Profit? | $79.14M | $80.45M | $50.59M | $46.62M | $35.20M | $18.43M | $30.60M | $24.54M | $16.15M | $4.88M |
| Gross Margin? | +83.3% | +91.2% | +64.6% | +70.9% | +73.4% | +56.6% | +98.6% | +96.3% | +96.3% | +71.6% |
| Operating Expenses? | $33.40M | $30.09M | $9.68M | $13.53M | $8.51M | $8.23M | $13.03M | $11.84M | $9.30M | $8.25M |
| Operating Income? | $45.73M | $48.01M | $40.91M | $33.08M | $26.70M | $10.20M | $16.69M | $12.21M | $6.80M | -$3.55M |
| EBITDA? | $57.20M | $56.28M | $41.70M | $33.84M | $28.19M | $10.64M | $16.78M | $12.26M | $6.85M | -$4.16M |
| Income Before Tax | $51.55M | $50.68M | $45.58M | $34.32M | $25.71M | $11.54M | $18.11M | $12.94M | $7.11M | -$3.15M |
| Income Tax Expense | $15.38M | $15.04M | $14.97M | $13.44M | $984,397 | -$3.51M | -$19,333 | -$281,779 | -$45,314 | -$609,059 |
| Net Income? | $36.17M | $35.64M | $30.60M | $20.88M | $24.73M | $16.65M | $18.13M | $13.22M | $7.18M | -$3.12M |
| EPS? | $0.72 | $0.72 | $0.62 | $0.42 | $0.50 | $0.31 | $0.38 | $0.28 | $0.15 | $-0.07 |
| Diluted EPS? | $0.72 | $0.70 | $0.59 | $0.40 | $0.48 | $0.30 | $0.37 | $0.27 | $0.14 | $-0.07 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality